Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · IEX Real-Time Price · USD
1.225
-0.035 (-2.78%)
At close: Jul 19, 2024, 4:00 PM
1.260
+0.035 (2.86%)
Pre-market: Jul 22, 2024, 7:26 AM EDT
Seres Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Seres Therapeutics stock have an average target of 5.75, with a low estimate of 1.25 and a high estimate of 10. The average target predicts an increase of 369.39% from the current stock price of 1.23.
Analyst Consensus: Buy
* Price targets were last updated on Jun 7, 2024.
Analyst Ratings
The average analyst rating for MCRB stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 1 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 1 | 0 |
| Hold | 1 | 1 | 1 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 7 | 7 | 7 | 4 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 7, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $15 → $10 | Strong Buy | Maintains | $15 → $10 | +716.33% | Jun 7, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $5 → $4 | Buy | Maintains | $5 → $4 | +226.53% | May 9, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $8 → $6 | Strong Buy | Maintains | $8 → $6 | +389.80% | May 8, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $9 → $5 | Buy | Maintains | $9 → $5 | +308.16% | Mar 6, 2024 |
Financial Forecast
Revenue This Year
n/a
from 126.33M
Revenue Next Year
5.95M
EPS This Year
-1.07
from -0.89
EPS Next Year
-0.79
from -1.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 36.8M | 335.7M | 10.0M | 621.9M |
| Avg | n/a | 6.0M | 108.6M | 3.3M | 340.3M |
| Low | n/a | n/a | n/a | n/a | 73.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 5,541.7% | -90.7% | 19,013.1% |
| Avg | - | - | 1,724.4% | -97.0% | 10,358.8% |
| Low | - | - | - | - | 2,158.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.99 | -0.57 | 0.72 | -0.75 | 3.71 |
| Avg | -1.07 | -0.79 | -0.04 | -0.85 | 3.60 |
| Low | -1.25 | -0.97 | -0.99 | -0.93 | 3.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.